Chong Kun Dang Holdings Corp. (KRX:001630)
South Korea · Delayed Price · Currency is KRW 48,500
+900 (1.89%)
At close: Nov 26, 2025
Chong Kun Dang Holdings Revenue
Chong Kun Dang Holdings had revenue of 234.22B KRW in the quarter ending September 30, 2025, with 0.85% growth. This brings the company's revenue in the last twelve months to 950.10B, down -0.54% year-over-year. In the year 2024, Chong Kun Dang Holdings had annual revenue of 957.75B with 8.86% growth.
Revenue (ttm)
950.10B
Revenue Growth
-0.54%
P/S Ratio
0.24
Revenue / Employee
25.68B
Employees
37
Market Cap
230.89B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 957.75B | 77.97B | 8.86% |
| Dec 31, 2023 | 879.78B | -29.18B | -3.21% |
| Dec 31, 2022 | 908.96B | -17.01B | -1.84% |
| Dec 31, 2021 | 925.98B | 67.86B | 7.91% |
| Dec 31, 2020 | 858.12B | 137.47B | 19.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 148.28B |